PBYI NASDAQ
Puma Biotechnology, Inc.
1W: +6.3%
1M: +11.1%
3M: +36.1%
YTD: +88.0%
1Y: +115.3%
3Y: +359.8%
5Y: +83.3%
$10.92
+0.07 (+0.65%)
After Hours: $11.38 (+0.46, +4.26%)
Weekly Expected Move ±6.4%
$10
$10
$11
$12
$12
Credit Risk of going bust: lower than 76% of companies Debt: 0.9% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.9%), Puma Biotechnology, Inc. would be worth roughly what it owes.
Total debt $4.8M against a stock market value of $560.1M.
Distance to default 8.78 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.4M (short-term plus half of long-term), stock volatility 60.8%; Altman Z'' -14.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.9%), Puma Biotechnology, Inc. would be worth roughly what it owes.
Total debt $4.8M against a stock market value of $560.1M.
Distance to default 8.78 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.4M (short-term plus half of long-term), stock volatility 60.8%; Altman Z'' -14.50. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (46)
Puma Biotechnology (NASDAQ:PBYI) Reaches New 12-Month High – Here’s Why
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
Puma Biotechnology (NASDAQ:PBYI) Sets New 12-Month High – Still a Buy?
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average – Here’s What Happened
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
What is Zacks Research’s Forecast for PBYI FY2026 Earnings?
Zacks Research Has Pessimistic Outlook of PBYI Q3 Earnings
3,804,736 Shares in Puma Biotechnology, Inc. $PBYI Bought by BlackRock Inc.
73,500 Shares in Puma Biotechnology, Inc. $PBYI Acquired by Canada Pension Plan Investment Board
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Earnings Preview: Puma Biotech (PBYI) Q2 Earnings Expected to Decline
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
Puma (PBYI) Q1 2026 Earnings Call Transcript
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Here are the major earnings after the close Thursday
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
Puma Biotechnology (NASDAQ:PBYI) Stock Price Passes Above 200 Day Moving Average – Should You Sell?
10 high-profitability small-cap stocks that are outperforming in 2026
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Puma Biotechnology (NASDAQ:PBYI) Stock Passes Above 200 Day Moving Average – What’s Next?
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?
Puma Biotechnology (NASDAQ:PBYI) Stock Crosses Above 200 Day Moving Average – Should You Sell?
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
Puma Biotechnology (NASDAQ:PBYI) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology (NASDAQ:PBYI) Shares Pass Above 200-Day Moving Average – What’s Next?
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
New Breast Cancer Therapy to Reduce Risk of Recurrence and Improve Disease-Free Survival Now Available in Thailand
Puma Biotechnology (NASDAQ:PBYI) Stock Price Crosses Above 200-Day Moving Average – Here’s What Happened
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)